The login/sign up screen for a Twitter account is seen on a laptop computer Tuesday, April 27, 2021, in Orlando, Fla. Twitter is rolling out a subscription service, starting in Canada and Australia, that offers perks like an undo button for subscribers. (AP Photo/John Raoux)
Twitter is rolling out a subscription service, starting in Canada and Australia, that offers perks like an undo button for subscribers.
The “Twitter Blue” subscription service will offer features that users have long asked for — but still no edit button. It includes bookmark folders for organizing saved content; an “Undo tweet" feature that gives users 30 seconds to cancel a sent tweet before it appears; a “reader mode" that makes threaded tweets easier to read; and customizable app icons and color themes.
Subscribers will also get dedicated customer support, meaning issues they report could get attention faster than other users.
The subscription costs 3.50 Canadian dollars ($2.89) a month and 4.50 Australian dollars ($3.45). There's no timeline for rolling out the service in other countries.
Twitter has been adding new features to attract new users. The social media site has nearly 200 million daily users, fewer than other social media networks. Facebook had 1.88 billion daily users on average in March 2021. Snapchat, meanwhile, had 280 million average daily active users in the first quarter.
Twitter shares closed Thursday down 15 cents at $57.01.
Adidas said it might have to write off the remaining 300 million euros ($320 million) worth of Yeezy shoes left unsold after it cut ties with rapper Ye, formerly known as Kanye West.
Ivanka Trump began testifying Wednesday in the civil fraud trial that is publicly probing the Trump family business, making an appearance she tried to prevent.
Walmart announced it's looking to create a calm morning shopping experience by turning TV walls to static non-moving images, silencing radios, and dimming store lights.
Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.
